Why I believe BPC-157/TB-500 will be a staple in post-op recovery following surgery: Surgery fixes the issue but there’s still an entire secondary process to get through, recovery. Recovery still has to solve four problems: blood supply, cell recruitment, collagen quality, and scar control. That’s the exact case for this stack. BPC-157: - Drives new capillaries into hypovascular tendon/ligament/incision tissue (VEGF / VEGFR2 / NO) - Turns on fibroblasts and organizes collagen instead of leaving a sloppy scar - Upregulates GH receptors on repair cells, so the body’s own growth signals get used better Current examples come from animal surgical model where they observed faster anastomosis/wound closure, better tendon-ligament alignment, improved load-to-failure, muscle-to-bone reattachment that otherwise fails. TB-500: - Moves repair cells into the defect (actin / cell migration) - Limits junk fibrosis so the repair stays mobile instead of glued down - Works more systemically, useful when the injury isn’t one tiny injection site - Parent compound (thymosin β4) has human wound-healing signal in dermal/ocular studies In combination with one another: - One builds the blood supply and architecture, while the other gets the cells there and keeps remodeling clean - Matches the actual failure modes of rotator cuff, Achilles, ACL/meniscus, labrum, and soft-tissue reconstructions We are still a long ways off from this happening. But it makes a lot of sense. Obviously there still needs to be a lot of human data done first. But in current research context it would make a ton of sense to have this stack follow majority of surgeries. Invasive and noninvasive alike!(CryptoDaddi)